HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.

Abstract
Caveolin-1 has a complex role in prostate cancer and has been suggested to be a potential biomarker and therapeutic target. As mature caveolin-1 resides in caveolae, invaginated lipid raft domains at the plasma membrane, caveolae have been suggested as a tumor-promoting signaling platform in prostate cancer. However, caveola formation requires both caveolin-1 and cavin-1 (also known as PTRF; polymerase I and transcript release factor). Here, we examined the expression of cavin-1 in prostate epithelia and stroma using tissue microarray including normal, non-malignant and malignant prostate tissues. We found that caveolin-1 was induced without the presence of cavin-1 in advanced prostate carcinoma, an expression pattern mirrored in the PC-3 cell line. In contrast, normal prostate epithelia expressed neither caveolin-1 nor cavin-1, while prostate stroma highly expressed both caveolin-1 and cavin-1. Utilizing PC-3 cells as a suitable model for caveolin-1-positive advanced prostate cancer, we found that cavin-1 expression in PC-3 cells inhibits anchorage-independent growth, and reduces in vivo tumor growth and metastasis in an orthotopic prostate cancer xenograft mouse model. The expression of α-smooth muscle actin in stroma along with interleukin-6 (IL-6) in cancer cells was also decreased in tumors of mice bearing PC-3-cavin-1 tumor cells. To determine whether cavin-1 acts by neutralizing caveolin-1, we expressed cavin-1 in caveolin-1-negative prostate cancer LNCaP and 22Rv1 cells. Caveolin-1 but not cavin-1 expression increased anchorage-independent growth in LNCaP and 22Rv1 cells. Cavin-1 co-expression reversed caveolin-1 effects in caveolin-1-positive LNCaP cells. Taken together, these results suggest that caveolin-1 in advanced prostate cancer is present outside of caveolae, because of the lack of cavin-1 expression. Cavin-1 expression attenuates the effects of non-caveolar caveolin-1 microdomains partly via reduced IL-6 microenvironmental function. With circulating caveolin-1 as a potential biomarker for advanced prostate cancer, identification of the molecular pathways affected by cavin-1 could provide novel therapeutic targets.
AuthorsH Moon, C S Lee, K L Inder, S Sharma, E Choi, D M Black, K-A Lê Cao, C Winterford, J I Coward, M T Ling, Australian Prostate Cancer BioResource, D J Craik, R G Parton, P J Russell, M M Hill
JournalOncogene (Oncogene) Vol. 33 Issue 27 Pg. 3561-70 (Jul 03 2014) ISSN: 1476-5594 [Electronic] England
PMID23934189 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ACTA2 protein, human
  • Actins
  • CAVIN1 protein, human
  • Caveolin 1
  • Interleukin-6
  • RNA-Binding Proteins
  • Receptors, Androgen
  • Proto-Oncogene Proteins c-akt
Topics
  • Actins (metabolism)
  • Aged
  • Animals
  • Caveolin 1 (metabolism)
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Transformation, Neoplastic
  • Disease Progression
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Interleukin-6 (metabolism)
  • Male
  • Membrane Microdomains (metabolism)
  • Mice
  • Middle Aged
  • Neoplasm Metastasis
  • Phosphorylation
  • Prostatic Neoplasms (metabolism, pathology)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • RNA-Binding Proteins (metabolism)
  • Receptors, Androgen (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: